Alera Bio is a next-generation biotechnology company focused on delivering transformative therapies for rare and neglected neurological disorders. By uniting scientific innovation with a deep sense of urgency, Alera Bio is accelerating solutions for patients and families who have long been overlooked. Grounded in translational research and strategic development, the company is built to drive meaningful impact where it matters most—at the intersection of biology, unmet medical need, and real-world patient outcomes. Headquartered in Chicago, IL, Alera Bio is actively identifying and evaluating therapeutic opportunities aligned with orphan drug and 505(b)(2) regulatory pathways. With a capital-efficient model and deep domain expertise, the company is positioned to rapidly advance development-ready assets that address urgent gaps in care for underserved neurological conditions.
Company Details
- Founded
- -
- Address
- Chicago, Illinois, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.alerabio.com/
- HQ
- Chicago, Illinois
- Competitors
- Cambridge Rare Disease Network (CamRARE), Pediatric Orthopaedic Society of North America (POSNA), Johnson & Johnson Innovative Medicine, Amgen, Michigan Rare Coalition, Pharmacy Management Solutions, Alume Biosciences, To Cure A Rose Foundation, Wilson Disease Association, BeOne Medicines.
Alera Bio Questions
Alera Bio's website is https://www.alerabio.com/
Alera Bio's LinkedIn profile is https://www.linkedin.com/company/alera-bio
Alera Bio's industry is
Biotechnology Research
Alera Bio's top competitors are
Cambridge Rare Disease Network (Camrare),
Pediatric Orthopaedic Society Of North America (Posna),
Johnson & Johnson Innovative Medicine,
Amgen,
Michigan Rare Coalition,
Pharmacy Management Solutions,
Alume Biosciences,
To Cure A Rose Foundation,
Wilson Disease Association,
Beone Medicines.
Alera Bio's categories are Biotechnology Research
Alera Bio's founding year is 2025
